<?xml version="1.0" encoding="UTF-8"?>
<p>Some risk factors may be explained by the virus's affinity for ACE2, which is expressed by the epithelial cells of the lung, intestine, kidney and vasculature.
 <xref rid="psb1843-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> ACE2 expression is upregulated in older people, tobacco smokers, and people with diabetes or hypertension, many of whom are treated with ACE inhibitors, and by the glitazones and ibuprofen. However, two recent studies from Italy and the USA
 <xref rid="psb1843-bib-0026" ref-type="ref">
  <sup>26</sup>
 </xref>, 
 <xref rid="psb1843-bib-0027" ref-type="ref">
  <sup>27</sup>
 </xref> have shown that treatment with an ACE inhibitor or angiotensin II‐receptor blocker (or indeed any other single antihypertensive agent) is not associated with an increased risk of contracting COVID‐19, severe symptoms or a fatal outcome. The link therefore appears to be simply due to the higher risk associated with cardiovascular disease.
</p>
